ViroGates A/S is a biotechnology company specializing in the development and commercialization of prognostic products for hospital use. The company is focused on improving healthcare outcomes by providing patented technology that assists medical professionals in predicting the course of diseases such as cancer and infectious diseases. ViroGates' flagship product, suPARnostic®, measures the level of the suPAR protein in blood samples, which is associated with various disease states and inflammation levels. By leveraging this diagnostic tool, hospitals can make more informed decisions regarding patient care and resource allocation. ViroGates A/S primarily serves healthcare providers, and its innovative solutions play a significant role in enhancing diagnostics and treatment strategies. Headquartered in Denmark, the company works towards advancing the healthcare sector with its cutting-edge prognostic techniques, boasting a presence that supports its market significance across the healthcare domain.